topic

818 Reheating the glioblastoma tumor microenvironment by direct conversion of glioblastoma to induced dendritic cell-like antigen presenting cells
Tianyi Liu, Dan Jin, Son Le, Dongjiang Chen, Mathew Sebastian, David Tran

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A916; DOI: 10.1136/jitc-2023-SITC2023.0818
819 Concurrent treatment with GM-CSF immunoembolization of hepatic metastases and systemic immune checkpoint inhibitors to overcome immune evasion in patients with metastatic uveal melanoma
Natalie J Miller, Jacob Leary, William McCamy, Joshua Veatch, Evan Hall, Wayne Monsky, Shailender Bhatia

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A917; DOI: 10.1136/jitc-2023-SITC2023.0819
820 ANV600 is a novel PD-1 targeted IL-2Rβ/γ agonist that is combinable with therapeutic PD-1 inhibitors
Patrizia Murer, Ulisse Salazar, Nicole Egli, Laetitia Petersen, Pia Neubert, Christian Stocker, Alexander Rau, Kirsten Richter, Andreas Katopodis, Christoph Huber

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A918; DOI: 10.1136/jitc-2023-SITC2023.0820
821 The combination of a trastuzumab ISAC and pertuzumab augments anti-tumor efficacy in multiple HER2+ tumor models relative to trastuzumab plus pertuzumab
Cecelia I Pearson, Andrew Luo, Karla A Henning, Anthony Lucas, David Omstead, Katelynn A McEachin, Paul D Ponath, Steven J Chapin, Shelley E Ackerman, Edith A Perez, Han K Kim, Michael N Alonso

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A919; DOI: 10.1136/jitc-2023-SITC2023.0821
822 IL6R-blockade abolishes the anti-tumor effect of TGFβ-derived immune modulatory vaccination in a murine model of pancreatic cancer
Maria Perez Penco, Lucia Lara de la Torre, Shawez Khan, Marco Donia, Mads Andersen

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A920; DOI: 10.1136/jitc-2023-SITC2023.0822
823 Repurposing CD26/DPP4 inhibitors to enhance immunotherapy response in pancreatic ductal adenocarcinoma
Maggie Phillips, Michael Ware, Natalie K Horvat, Jacklyn Hammons, Megan M Wyatt, Thomas Mace, Shishir Maithel, Juan Sarmiento, Olatunji Alese, Bassel FEl Reyes, Chrystal M Paulos, Gregory B Lesinski

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A921; DOI: 10.1136/jitc-2023-SITC2023.0823
824 Synergistic effects of a therapeutic cancer vaccine, an immunocytokine, and an HDAC inhibitor in an HPV tumor model
Lisa K Poppe, Nicholas Roller, Miriam Marlene Medina-Enríquez, Jeffrey Schlom, Caroline Jochems Frohlich

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A922; DOI: 10.1136/jitc-2023-SITC2023.0824
825 α-CD38 therapy reverses α-PD1 resistance when used in a proper biologic schedule; explaining and overcoming previous failures of the combination in clinical trials
Christopher Priestley-Milianta

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A923; DOI: 10.1136/jitc-2023-SITC2023.0825
826 Differential effect of NKG2A blockade on peripheral and intra-tumoral CD8 T cell response induced by KISIMA – VSV-GP-TAg heterologous prime-boost vaccination
Erika Riva, Susanna Carboni, Wilma Besson-Di Berardino, Mati Moyat, Elodie Belnoue, Laetitia Devy-Dimanche, Matteo Rossi

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A924; DOI: 10.1136/jitc-2023-SITC2023.0826
827 Abstract withdrawn
Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A925; DOI: 10.1136/jitc-2023-SITC2023.0827

Main menu

topic

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

topic

Pages